The National Cancer Institute’s Nanodelivery Systems and Devices Branch has compiled the following list of funding opportunities and translational resources that may be of interest to nanotech developers. Click the link for each announcement to learn more.
- PAR 17-240 – Innovative Research in Cancer Nanotechnology (R01). The proposal should address major barriers in cancer biology and/or oncology using nanotechnology and should emphasize a fundamental understanding of nanomaterial and/or nanodevice interactions with biological systems. Remaining receipt dates: Nov 21, 2019, and May 21, 2020. We anticipate this PAR will be renewed.
Clinical/Translational Programs and Funding Opportunities:
- PAR-18-560: Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required). The FOA supports research projects that implement early phase (Phase 0, I, and II) investigator-initiated clinical trials focused on cancer-targeted diagnostic and therapeutic interventions of direct relevance to the research mission of NCI’s Division of Cancer Treatment and Diagnosis (DCTD). Due Standard Dates through Jan 8, 2021.
- PAR-18-011: Early Phase Clinical Trials in Imaging and Image-Guided Interventions (R01 Clinical Trial Required). This FOA supports clinical trials in the preliminary evaluation of the safety and efficacy of imaging agents, and the assessment of imaging systems, image processing, and other quantitative tools. Due October 11, 2019, and February 14, 2020.
- NCI Experimental Therapeutics Program (NExT): Please note that the NExT Program is not a grant mechanism; applications with exceptional science cannot be accepted without a clear path to the clinic or potential benefit to patients. The mission of the NExT Program is to advance clinical practice and bring improved therapies to patients with cancer by supporting the most promising new drug discovery and development projects. Awardees will not necessarily receive direct funding; rather, the NCI may allocate various contract and grant resources toward the implementation and development of submitted projects. The NCI will partner with successful applicants to facilitate the milestone-driven progression of new anticancer drugs (small molecules, biologics) and imaging agents towards clinical evaluation and registration. See application instructions.
- The Experimental Therapeutics Clinical Trials Network (ETCTN). The ETCTN supports the early phase clinical trials of NCI Investigational New Drug (IND) agents by providing investigators and programs with expertise in early drug development and translational research. There are two expired FOAs for this program, but Investigators are encouraged to check back to the Network website link above.
- RFA-CA-19-007 (UM1) is open to any qualified applicant and solicits applications from multidisciplinary groups that can assemble an appropriate infrastructure and conduct phase 0, 1, 2, pilot and other experimental therapeutics clinical trials involving agents for which NCI have received the IND status.
- RFA-CA-19-008 (U24) intends to create Pharmacokinetics Resource Laboratories to support the ETCTN.
Basic/Applied Science Programs and Funding Opportunities:
- PAR-19-363: Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional). This FOA supports the integration of imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer treatment to determine the optimal use of these modalities in the characterization of therapy response or detecting the emergence of resistance. Due Standard Dates through May 8, 2021.
- RFA-CA-049/050: Revision Applications for Mechanism of Drug Resistance (U01 Clinical Trial Not Allowed/R01 Clinical Trial Not Allowed). These Moonshot RFAs support the addition of new aims and directions to ongoing NCI-funded research projects on underlying mechanisms of resistance, preclinical design and foster development of single or combination therapies to effectively target resistant/refractory tumors and/or their microenvironment at the clinical level. Due October 24, 2019; June 24, 2020; October 22, 2020; and June 23, 2021.
- PAR-19-156/157: Bioengineering Research Partnerships (U01 Clinical Trial Not Allowed). These FOAs intend to accelerate the development and adoption of promising tools and technologies that can address important biomedical problems. Due Standard Dates through Jan 8, 2022.
- PA-19-112/111: Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (R01 Clinical Trial Optional, R21 Clinical Trial Optional). This FOA encourages collaborative applications that will contribute to the identification and characterization of patients at risk of developing cancer treatment-related cardiotoxicity. Due Standard Dates through Jan 8, 2022.
- The Innovative Molecular Analysis Technologies (IMAT) Program: The IMAT RFAs encourage applications from individuals and groups interested in developing novel technologies suitable for the molecular analysis of cancers and their host environment in support of basic, clinical, and epidemiological research. The NCI has approved the reissuance for funding opportunity announcements, so investigators are encouraged to check back on the link above.
Team Science Funding Opportunities
- PAR-18-290: National Cancer Institute Program Project Applications (P01 Clinical Trial Optional). The investigator-initiated P01 proposal should include at least three R01-like research projects (which share a common central theme, focus, and an overall objective), Administrative core, and optional Shared Resource Core. Due Standard Dates through Jan 2020. This PAR will be renewed.
- PAR-18-530: Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 Clinical Trial Optional). This FOA intends to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and manage disease. Due Standard Dates through Jan 8, 2021.
- PAR-18-009: Academic-Industrial Partnerships to Translate and Validate in vivo Cancer Imaging Systems (R01 Clinical Trial Optional). Similar to PAR-18-530, this FOA intends to stimulate translations of scientific discoveries and engineering developments in imaging or spectroscopic technologies into methods or tools that address problems in cancer biology, risk of cancer development, diagnosis, treatment, and/or disease status. Due Standard Dates through Nov 6, 2019.